Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HINT1 | P49773 | 4/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25505327 | 1.00 | KDM4E (0.59) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL25504740 | 0.95 | KDM4E (0.66) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL12017695 | 0.91 | KDM4E (0.54) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL25504668 | 0.89 | KDM4E (0.45) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL23898886 | 0.88 | KDM4E (0.54) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL24102841 | 0.88 | KDM4E (0.54) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL13255821 | 0.86 | KDM4E (0.54) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL20248707 | 0.86 | KDM4E (0.47) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL25680113 | 0.86 | KDM4E (0.47) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL18510989 | 0.86 | KDM4E (0.46) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198251-B2 | Combination motif immune stimulatory oligonucleotides with improved activity | COLEY PHARMACEUTICAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090087446-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | COLEY PHARMACEUTICAL GMBH | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087446-A1 | COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY | STING1, IFNG, RNGTT | KDM4E 1390/4885POLA1 115/4885TAS1R3 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.